Benign Prostatic Hyperplasia. Shahideh Amini Pharm.D clinical pharmacy resident Tehran university of medical science Department of pharmacotherapy
|
|
- Kelly Weaver
- 5 years ago
- Views:
Transcription
1
2 Benign Prostatic Hyperplasia Shahideh Amini Pharm.D clinical pharmacy resident Tehran university of medical science Department of pharmacotherapy
3 Definition BPH is a common disorder that increases in frequency progressively with age in men older than 50 years is a condition that occurs when the prostate enlarges, potentially slowing or blocking the urine stream
4 Clinical Manifestations increased frequency of urination, nocturia, hesitancy, urgency, and weak urinary stream. These symptoms typically appear slowly and progress gradually over a period of years
5 Clinical Manifestations Obstructive symptoms: Urinary hesitancy urine dribbles out of penis Sense of incomplete emptying Irritative signs: Nocturia,Urgency,Frequency Complication: Chronic kidney disease Gross hematuria Urinary incontinence Recurrent tract infection Bladder stone
6 a normal prostate gland in an adult man weighs 4 to 20 g. The prostate has two major functions: (a) To secrete fluids that make up a portion (20% 40%) of the ejaculate volume; (b) To provide secretions with possible antibacterial effect related to its high concentration of zinc
7 The prostate is a male reproductive gland that produces Aging the fluid that carries sperm decrease during ejaculation in testicular testostrone androgen production in the 5-alpha-reductase aging male dihydrotestosterone
8 Phathophysiology The cause of BPH is unclear most hypothesies are based on hormonal and aging processes. The prostate gland comprises 3 types of tissue: Epithellial or glandular produces prostatic secretions. These secretion are delivered into the urethra during ejaculation and contribute to the ultimate ejaculate volume. Androgens stimulate epithelial tissue growth. Stromal or smooth muscle Is embedded with α1-adrenergic receptors Capsule
9 Phathophysiology BPH commonly results from both static and dynamic. Static :Gradual enlargement of prostate Dynamic:agents or situations that α-adrenergic tone and constrict the gland smoooth muscle.
10 Phathophysiology Androgen testostrone 5-alpha-reductase activity (type 2) dihydrotestosterone Estrogen Prostatic stromal cells contain estrogen receptors, and the concentrations are lower in hyperplastic than in normal prostatic tissue. increase in the estrogen/androgen ratio in prostatic tissue, especially in the stroma.
11 Clinical Manifestations
12 Clinical Manifestations Obstructive symptoms: Urinary hesitancy urine dribbles out of penis Sense of incomplete emptying Irritative signs: Nocturia,Urgency,Frequency Complication: Chronic kidney disease Gross hematuria Urinary incontinence Recurrent tract infection Bladder stone
13 AUA Symptom Score Sheet Not at all Less than 1 time in 5 Less than half the time About half the time More than half the time Almost always Your score Incomplete emptying Over the past month, how often have you had a sensation of not emptying your bladder completely after you finish urinating? Frequency Over the past month, how often have you had to urinate again less than two hours after you finished urinating? Intermittency Over the past month, how often have you found you stopped and started again several times when you urinated? Urgency Over the last month, how difficult have you found it to postpone urination? Weak stream Over the past month, how often have you had a weak urinary stream? Straining Over the past month, how often have you had to push or strain to begin urination? None 1 time 2 times 3 times 4 times 5 times or more Your score Nocturia Over the past month, many times did you most typically get up to urinate from the time you went to bed until the time you got up in the morning? Quality of life due to urinary symptoms Delighted Pleased Mostly satisfied Mixed about equally satisfied and dissatisfied Mostly dissatisfied Unhappy Terrible If you were to spend the rest of your life with your urinary condition the way it is now, how would you feel about that? Total score: 0-7 Mildly symptomatic; 8-19 moderately symptomatic; severely symptomatic.
14 Diagnosis Medical history Physical examination Laboratory tests Blood urea nitrogen (BUN) Prostate specific antigen (PSA)
15 Diagnosis Physical examination A digital rectal examination should be done to assess prostate size and consistency and to detect nodules, indurations, and asymmetry, all of which raise suspicion for malignancy Urinalysis to detect urinary infection and blood, which could indicate bladder cancer or calculi.
16 Diagnosis Serum prostate specific antigen (PSA) The specificity of the serum PSA assay in men with obstructive symptoms is less than in asymptomatic men. Prostate cancer can cause obstructive symptoms, although the presence of symptoms is not predictive of prostate cancer Measurements of serum PSA may be used as a screening test for prostate cancer in these men with BPH, preferably in men between the ages of 50 to 69 years and before therapy for BPH is discussed.
17 Diagnosis Post-void residual urine volume Determined by in-out catheterization, radiographic methods, or ultrasonography. Normal men have less than 12 ml of residual urine. In addition to being a possible indicator of BPH, a large residual volume is probably associated with increased risk of infection and is a precursor to bladder decompensation
18 Diagnosis SerumA high serum creatinine may be due to bladder outlet obstruction or to underlying renal or prerenal disease; it also increases the risk for complications and mortality after prostatic surgery. creatinine concentration
19 untreated BPH can cause acute urinary retention, recurrent urinary tract infections, hydronephrosis, and even renal failure. Age, symptoms, urinary flow rate and prostate volume are risk factors for acute urinary retention.
20 Treatment
21 SELF-CARE Urinate when you first get the urge. Also, go to the bathroom when you have the chance, even if you don't feel a need to urinate. Avoid alcohol and caffeine, especially after dinner. Don't drink a lot of fluid all at once. Spread out fluids throughout the day. Avoid drinking fluids within 2 hours of bedtime. Try NOT to take over-the-counter cold and sinus medications that contain decongestants or antihistamines. These medications can increase BPH symptoms. Keep warm and exercise regularly. Cold weather and lack of physical activity may worsen symptoms. Learn and perform Kegel exercises (pelvic strengthening exercises). Reduce stress. Nervousness and tension can lead to more frequent urination
22 Treatment 5α-Reductase Inhibitors Alpha-1-adrenergic antagonists
23 Treatment α-adrenergic antagonists do not decrease prostate volume or PSA levels. α-adrenergic antagonists are associated with less sexual dysfunction than are 5α-reductase inhibitors α-adrenergic antagonists which is faster acting and more effective than a 5α-reductase inhibitor.
24 Treatment A 5α-reductase inhibitor is a good first-choice agent in patients with a significantly enlarged prostate (>40 g) who cannot tolerate the cardiovascular adverse effects of α1- adrenergic antagonists. In patients at risk for developing complications of BPH, specifically patients with an enlarged prostate gland greater than 40 g and an elevated PSA 1.4 ng/ml, combination drug therapy with an α1-adrenergic antagonist and a 5α-reductase inhibitor is more beneficial than single drug therapy.
25 Treatment Alpha-1-adrenergic antagonists Five long-acting alpha-1- antagonists, terazosin, doxazosin, tamsulosin, alfuzosin, and silodosin have been approved by the Food and Drug Administration in the United States for treatment of the symptoms of BPH. Prazosin, a shortacting alpha-1-antagonist, is generally not used for BPH, due to need for frequent dosing and the potential for more cardiovascular side effe Mechanism Alpha-1-adrenergic antagonists such as terazosin act against the dynamic component of bladder outlet obstruction. Prostatic tissue contains two types of alpha-adrenergic receptors: alpha-1 and alpha-2.alpha-1 receptors are abundant in the prostate and base of the bladder, and sparse in the body of the bladder.the density of these receptors is increased in hyperplastic prostatic tissue.alpha-1-adrenergic antagonists target alpha-1a receptors (largely in prostatic smooth muscle) and alpha-1d receptors (largely in bladder detrusor smooth muscle).
26 Treatment Terazosin, doxazosin, and alfuzosin are second-generation α- adrenergic antagonists. They antagonize peripheral vascular α1-adrenergic receptors in addition to those in the prostate. Therefore, their adverse effects include first-dose syncope, orthostatic hypotension, and dizziness. Alfuzosin is less likely to cause cardiovascular adverse effects than other secondgeneration agents. To minimize orthostatic hypotension and first-dose syncope with terazosin and doxazosin, patients should be slowly titrated to a maintenance dose and should take these drugs at bedtime.
27 Treatment differ in terms of duration of action and dosage formulation. prazosin requires dosing two to three times per day, terazosin, doxazosin, and alfuzosin offer more convenient once-daily dosing. Because prazosin requires twice to thrice-daily dosing and has significant cardiovascular adverse effects, it is not recommended in the current
28
29 Treatment Reduces dynamic factor Blocks α1-adrenergic receptors in prostatic stromal tissue Alfuzosin (UroXatral) Terazosin (Hytrin) Doxazosin (Cardura) 10 mg PO daily 1-10 mg PO daily 1-8 mg PO daily Blocks α -1A receptors in the prostate Tamsulosin (Flomax) mg PO daily
30 Terazosin Oral: Initial: 1 mg at bedtime, increasing as needed; most patients require 10 mg day. If no response after 4-6 weeks of 10 mg/day, may increase to 20 mg/day. ADVERSE REACTIONS postural hypotension, dizziness, somnolence, nasal congestion/rhinitis, and impotence
31 Terazosin CONTRAINDICATIONS Hypersensitivity to quinazolines (doxazosin, prazosin, terazosin) or any component of the formulation; concurrent use with phosphodiesterase-5 (PDE-5) inhibitors including sildenafil (>25 mg), tadalafil, or vardenafil WARNINGS / PRECAUTIONS Angina: Discontinue if symptoms of angina occur or worsen Orthostatic hypotension/syncope
32 Tamsulosin (Flomax ) Tamsulosin, the only third-generation α-adrenergic antagonist, is selective for prostatic α 1A receptors. Therefore, tamsulosin does not cause peripheral vascular smooth muscle relaxation. Tamsulosin is a good choice for patients who cannot tolerate hypotension; have severe coronary artery disease, volume depletion, cardiac arrhythmias, severe orthostasis, or liver failure; or are taking multiple antihypertensives. Tamsulosin is also suitable for patients who want to avoid the delay of dose titration or to avoid dosing only at bedtime. Caution is needed to avoid potential drug interactions. Tamsulosin decreases metabolism of cimetidine and diltiazem. Carbamazepine and phenytoin increase catabolism of α- adrenergic antagonists.
33 Tamsulosin (Flomax ) Oral: tamsulosin should be taken on an empty stomach because food decreases the drug s bioavailability and reduces the peak The onset of peak action is quick, in the range of 1 week, and only a minority of patients will require up-titration to a higher daily dose. No decreases in blood pressure or increases in heart rate have been reported in normotensive patients, the elderly, subgroups of patients with well-controlled hypertension,or those with uncontrolled hypertension
34 Tamsulosin (Flomax ) Tiredness and asthenia, ejaculatory dysfunction, flu-like symptoms, and nasal congestion are the most common dose-related adverse effects of tamsulosin
35 Tamsulosin (Flomax ) WARNINGS / PRECAUTIONS Angina: Discontinue if symptoms of angina occur or worsen Orthostatic hypotension/syncope Priapism: Sulfonamide allergy
36 to avoid α1-adrenergic antagonists for 4 hours after taking a dose of one of these phosphodiesterase inhibitors. The exception is tadalafil, which can be taken together with tamsulosin 0.4 mg.
37
38 Treatment 5α-Reductase Inhibitors 5α -Reductase inhibitors are the only agents approved for BPH by (FDA) that interfere with the stimulatory effect of testosterone. These agents slow disease progression and decrease the risk of complications. Compared with α-adrenergic antagonists,5α -reductase inhibitors have the disadvantages of requiring 6 months to maximally shrink an enlarged prostate, being less likely to induce objective improvement, and causing more sexual dysfunction.
39 Treatment 5α -Reductase inhibitors reduce serum PSA levels by 50%. Therefore, PSA should be measured at baseline and, for monitoring purposes, subsequent measurements should be doubled. 5α -Reductase inhibitors are in FDA pregnancy category X and are therefore contraindicated in pregnant females. Pregnant and potentially pregnant women should not have contact with semen from men receiving 5α -Reductase inhibitors
40 Treatment Reduces static factor Blocks 5 α - reductase enzyme Finasteride (Proscar) Dutasteride (Avodart) 5 mg PO daily 0.5 mg PO daily Blocks dihydrotestosterone at its intracellular receptor Bicalutamide (Casodex) 50 mg PO daily
41 Finasteride Benign prostatic hyperplasia (Proscar ) Oral: 5 mg/day as a single dose; clinical responses occur within 12 weeks to 6 months of initiation of therapy; long-term administration is recommended for maximal response Male pattern baldness (Propecia ): Oral: 1 mg daily Female hirsutism (unlabeled use): Oral: 5 mg/day
42 Finasteride CONTRAINDICATIONS Hypersensitivity to finasteride or any component of the formulation; pregnancy; not for use in children WARNINGS / PRECAUTIONS Special handling: Hazardous agent: Use appropriate precautions for handling and disposal. Women/pregnancy: Women can absorb the active ingredient through the skin and should always use caution whenever handling. Pregnant women or women trying to conceive should not handle the product; finasteride may negatively impact fetal development.
43
44 Hypothalamus Gn-RH (LHRH) Pituitary Prostate Cell Growth LH + FSH Testes Prostatic cells Testosterone 5-alpha-reductase DHT
45 Treatment Reduces static factor Flutamide (Eulexin) Leuprolide (Lupron) mg PO t.i.d. 7.5 mg IM monthly or 22.5 mg IM every 3 months Nafarelin 400 mcg SC daily
46 Treatment OTHER STRATEGIES: Patients with BPH should avoid medications that can exacerbate symptoms or induce urinary retention. These include anticholinergic medications such as sedating antihistamines, and adrenergic agents such as decongestants. Behavioral modifications may be helpful. These include avoiding fluids prior to bedtime or before going out, reducing consumption of mild diuretics such as caffeine and alcohol, and double voiding to empty the bladder more completely.
47 Antimuscarinics Some men with have obstructive symptoms, such as frequency, urgency, and incontinence, related to an overactive bladder. Bladder contractions are stimulated by acetylcholine effects on muscarinic receptors in smooth muscle of the bladder. Use of antimuscarinic agents should be restricted to men with low post-void residual volumes.
48 tolterodine for reduction of urgency episodes and frequency. Oxybutynin has direct antispasmodic effects and inhibits the action of acetylcholine on smooth muscle. was superior to tolterodine for reduction of incontinence
49 SURGICAL INTERVENTION Prostatectomy, performed transurethrally or suprapubically, is the gold standard for treatment of patients with moderate or severe symptoms of BPH and for all patients with complications.
50 The choice of a specific surgical procedure is usually based on the severity of your symptoms and the size and shape of your prostate gland. Transurethral resection of the prostate (TURP): This is the most common and most proven surgical treatment for BPH. TURP is performed by inserting a scope through the penis and removing the prostate piece by piece. Transurethral incision of the prostate (TUIP): This procedure is similar to TURP, but is usually performed in men who have a smaller prostate. It is usually performed without the need for a hospital stay. Like TURP, a scope is inserted through the penis until the prostate is reached. Then, rather than removing the prostate, a small incision is made in the prostate tissue to enlarge the opening of the urethra and bladder outlet. Simple prostatectomy: An open prostatectomy is usually performed using general or spinal anesthesia. An incision is made through the abdomen or perineum (the area behind the scrotum). Only the inner part of the prostate gland is removed. The outer portion is left behind. This is a lengthy procedure, and it usually requires a hospital stay of 5 to 10 days
51 EVALUATION OF THERAPEUTIC OUTCOMES The primary therapeutic outcome of BPH therapy is restoring adequate urinary flow without causing adverse effects. Outcome depends on the patient's perception of effectiveness and acceptability of therapy.objective measures of bladder emptying (e.g., uroflowmeter and postvoid residual urine volumes) are also useful after 6 to 12 months of 5α-reductase inhibitor therapy or 3 to 4 weeks of α -adrenergic antagonist therapy. Laboratory tests (e.g., BUN, creatinine, PSA) and urinalysis should be monitored regularly. In addition, patients should have an annual digital rectal examination. If PSA does not decrease by 50% after 6 months of 5α -reductase inhibitor therapy, the patient should be evaluated for prostate cancer.
52 Prostate cancer & BPH BPH is not believed to be a risk BPH factor occurs for primarily prostate cancer, in the central although or transitional studies have zone come of to the prostate, conflicting while results prostate cancer originates primarily in the peripheral part of the prostate
53 از توجه شما متشکرم
54 finasteride often suppresses the hematuria
MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH
MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH INTRODUCTION (1) Part of male sexual reproductive organ Size
More informationBenign Prostatic Hyperplasia. Management of Benign Prostatic Hyperplasia. Goals of Therapy
Benign Prostatic Hyperplasia Management of Benign Prostatic Hyperplasia Goals of Therapy Improve or abolish lower urinary tract symptoms (LUTS) Prevent or delay clinical progression of benign prostatic
More informationBenign Prostatic Hyperplasia (BPH):
Benign Prostatic Hyperplasia (BPH): Evidence Based Guidelines for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the pathophysiology and prevalence of BPH 2. Select the appropriate
More informationVictoria Sharp, MD, MBA, FAAFP. Clinical Professor of Urology and Family Medicine
Victoria Sharp, MD, MBA, FAAFP Clinical Professor of Urology and Family Medicine Victoria Sharp, MD, MBA, FAAFP Market Chief Medial Officer AmeriHealth Caritas Family of Companies Office phone: (515) 330-3740
More informationBenign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia (BPH) Definition Prostate gland enlargement is a common condition as men get older. Also called benign prostatic hyperplasia (BPH), prostate gland enlargement can cause bothersome
More information10/9/2015. Dana A. Brown, Pharm.D., BCPS Assistant Dean for Academics, Associate Professor of Pharmacy Practice Palm Beach Atlantic University
Dana A. Brown, Pharm.D., BCPS Assistant Dean for Academics, Associate Professor of Pharmacy Practice Palm Beach Atlantic University 1. Explain the pathophysiology of benign prostatic hyperplasia (BPH),
More informationBenign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary
Benign Prostatic Hyperplasia Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied,
More informationBenign Prostatic Hyperplasia (BPH) IPT VI Srikanth Kolluru, Ph.D
Benign Prostatic yperplasia (BP) IPT VI Srikanth Kolluru, Ph.D. kolluru@tamhsc.edu, 361 221 0741 verview 1. Introduction and background of BP 2. Causes and common symptoms 3. Treatment options Learning
More information50% of men. 90% of men PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS. Want more information? What are the symptoms?
PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS What is Benign Prostatic Hyperplasia (enlarged prostate)? Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate, the gland that
More informationProstate Disease. Chad Baxter, MD
Prostate Disease Chad Baxter, MD Managing BPH and LUTS Chad Baxter, MD Department of Urology cbaxter@mednet.ucla.edu 33 nd Annual UCLA Intensive Course in Geriatric Medicine & Board Review Prevalence of
More informationMEDICAL THERAPY. Endocrine Approaches. Página 1 de 5.
Página 1 de 5 MEDICAL THERAPY Part of "32 - BENIGN PROSTATIC HYPERPLASIA" Use of pharmacologically defined and a variety of so-called alternative medications to attempt to improve BPH voiding dysfunction
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Benign prostatic hyperplasia (BPH), also called benign prostatic hypertrophy or benign prostatic obstruction, is a condition in
More informationMODULE 3: BENIGN PROSTATIC HYPERTROPHY
MODULE 3: BENIGN PROSTATIC HYPERTROPHY KEYWORDS: Prostatic hypertrophy, prostatic hyperplasia, PSA, voiding dysfunction, lower urinary tract symptoms (LUTS) At the end of this clerkship, the medical student
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablative therapies, transurethral needle ablation, Adverse events, sexual side effects of BPH Aging, and incidence of BPH associated with
More informationAll about the Prostate
MEN S HEALTH Dr Nick Pendleton January 16 th 2018 All about the Prostate 1 What does it do? Functions of the Prostate 1. Secretes Prostatic Fluid slightly alkaline fluid, 30% of volume of seminal fluid,
More informationProstate Health PHARMACIST VIEW
Prostate Health PHARMACIST VIEW Prostate Definition Prostate is a gland made of fibromuscular tissue. It is about 4 cm and surrounds the neck of the bladder and the urethra. It produces seminal fluid.
More informationPROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA. A Minimally Invasive Innovative Treatment
PROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA A Minimally Invasive Innovative Treatment What is the prostate? The prostate is an accessory organ of the male reproductive system.
More informationWhat is Benign Prostatic Hyperplasia (BPH)?
What is Benign Prostatic Hyperplasia (BPH)? Benign prostatic hyperplasia (BPH) is an enlarged prostate. The prostate goes through two main growth periods as a man ages. The first occurs early in puberty,
More informationSome prostatic diseases
Some prostatic diseases Benign Prostatic Hyperplasia (Nodular Hyperplasia) Extremely common Present in a significant number of men by the age of 40 & its frequency rises progressively with age, reaching
More informationRole of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia
[Medicine Update (2003): 11(2), 55-58] Role of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia Arora, R.P., CMO, Rajiba L.
More informationUrinary tract disorders
Urinary tract disorders Medicines Formulary Contents: 1. Urinary retention 1 2. Urinary incontinence 2 3. Urethral pain prevention during catheterisation 3 4. Indwelling catheters maintenance of patency
More informationDisclosures. Geriatric Incontinence and Voiding Dysfunction. Agenda. Agenda. UI: a Geriatric Syndrome. Geriatric Syndromes 9/7/2018.
Disclosures Geriatric Incontinence and Voiding Dysfunction None Shachi Tyagi MD, MS Assistant Professor Division of Geriatric Medicine University of Pittsburgh Medical Center UI: a Geriatric Syndrome Geriatric
More informationTHE JOHNS HOPKINS WHITE PAPERS. prostate Disorders
THE JOHNS HOPKINS WHITE PAPERS prostate Disorders 2 0 1 0 H. Ballentine Carter, M.D. JOHNS HOPKINS MEDICINE BALTIMORE, MARYLAND Dear Reader: Welcome to the 2010 Prostate Disorders White Paper your personal
More informationMini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano
Dipartimento di Urologia Direttore Prof. Giorgio Guazzoni Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano alberto.saita@humanitas.it
More informationVoiding Dysfunction Block lecture, 5 th year student. Choosak Pripatnanont, Department of Surgery, PSU.
Voiding Dysfunction 2009 Block lecture, 5 th year student. Choosak Pripatnanont, Department of Surgery, PSU. Objectives Understand and explain physiologic function and dysfunction of lower urinary tract.
More informationLower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics. Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital
Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital 01/02/2018 Lower Urinary Tract Symptoms LUTS - one of
More informationPatient Expectations Following Greenlight XPS
Patient Expectations Following Greenlight XPS 1. Hematuria it is common for men to have light pink to cherry red urine following the procedure. This small amount of blood in the urine usually resolves
More informationMen s Health Topics. Learning Objectives. BPH Definition. The Prostate Gland. I have nothing to disclose. Mindi Miller, Pharm. D.
I have nothing to disclose Men s Health 2016 Mindi Miller, Pharm. D., BCPS Topics Benign Prostatic Hyperplasia Erectile Dysfunction Learning Objectives Describe common lower urinary tract symptoms (LUTS)
More informationProstate Enlargement: Benign Prostatic Hyperplasia
Prostate Enlargement: Benign Prostatic Hyperplasia National Kidney and Urologic Diseases Information Clearinghouse What is benign prostatic hyperplasia? Benign prostatic hyperplasiaalso called BPHis a
More informationBenign Prostatic Hyperplasia A Management Update for Pharmacists
A Management Update for Pharmacists Tom Smiley, PharmD This program has been approved for 1.0 CEUs by the Canadian Council on Continuing Education in Pharmacy CCCEP #1043-2010-087-I-P This lesson is valid
More information(dutasteride/tamsulosin) For the treatment of Benign Prostatic Hyperplasia (BPH)
Combodart (dutasteride/tamsulosin) For the treatment of Benign Prostatic Hyperplasia (BPH) This leaflet is only for use by patients who have been prescribed Combodart. Please see Patient Information Leaflet
More informationCooled ThermoTherapy TM
Are BPH Medications Weighing You Down? Think Outside the Pillbox Cooled ThermoTherapy TM A non-surgical, 30 minute in-office treatment that provides long-term relief from BPH symptoms and urinary obstruction
More informationCialis. Cialis (tadalafil) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.06.02 Subject: Cialis Page: 1 of 5 Last Review Date: September 18, 2015 Cialis Description Cialis (tadalafil)
More informationCanadian Undergraduate Urology Curriculum (CanUUC): Prostate Diseases
Canadian Undergraduate Urology Curriculum (CanUUC): Prostate Diseases LUTS/Benign Prostate Hyperplasia Objectives 1. List the lower urinary tract symptoms (LUTS) found in men with BPH. 2. List the differential
More informationDuring the past decade, numerous
Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men. It is estimated that by age 60 years, greater than 50% of men will have histologically documented evidence of the disease.
More informationBenign prostatic hyperplasia (BPH)
Diseases and Conditions Benign prostatic hyperplasia (BPH) By Mayo Clinic Staff Prostate gland enlargement is a common condition as men get older. Also called benign prostatic hyperplasia (BPH), prostate
More informationDOWNLOAD OR READ : TREATMENT OF BENIGN PROSTATIC HYPERPLASIA PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : TREATMENT OF BENIGN PROSTATIC HYPERPLASIA PDF EBOOK EPUB MOBI Page 1 Page 2 treatment of benign prostatic hyperplasia treatment of benign prostatic pdf treatment of benign prostatic
More informationKey words: Lower Urinary Tract Symptoms (LUTS), Prostatic Hyperplasia, Alpha-1 Adrenoceptor Antagonists, Tamsulosin, Terazosin.
The Professional Medical Journal DOI: 10.17957/TPMJ/17.4102 ORIGINAL PROF-4102 PROSTATIC HYPERPLASIA; COMPARISON BETWEEN TAMSULOSIN AND TERAZOSIN FOR EFFICACY IN MEDICAL MANAGEMENT OF LOWER URINARY TRACT
More informationCialis. Cialis (tadalafil) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.22 Subject: Cialis Page: 1 of 5 Last Review Date: September 15, 2017 Cialis Description Cialis (tadalafil)
More informationURGE MOTOR INCONTINENCE
URGE MOTOR INCONTINENCE URGE INCONTINENCE COMMONEST TYPE IN ELDERLY WOMEN Causes: 1 - Defects in CNS regulation Stroke Parkinson s disease Dementia (Alzheimer s and other types) Normopressure hydrocephalus
More informationManagement of LUTS after TURP and MIT
Management of LUTS after TURP and MIT Hong Sup Kim Konkuk University TURP & MIT TURP : Gold standard MIT TUIP TUNA TUMT HIFU LASER Nd:YAG, ILC, HoLRP, KTP LUTS after TURP and MIT Improved : about 70% Persistent
More informationBenign Prostatic Hyperplasia Case Study 2. Medical Student Case-Based Learning
Benign Prostatic Hyperplasia Case Study 2 Medical Student Case-Based Learning The Case of Mr. Presley s Urinary Retention Mr. Presley presents to the emergency department in urinary retention. You are
More informationManagement of LUTS. Simon Woodhams February 2012
Management of LUTS Simon Woodhams February 2012 The management of lower urinary tract symptoms (LUTS) in men Implementing NICE guidance May 2010 NICE clinical guideline 97 Background Lower urinary tract
More informationSaving. Kidneys. Benign Prostate Disease
Saving Kidneys 9 Benign Prostate Disease This booklet will tell you more about the prostate gland. Its functions and benign hyperplasia have been defined in a simple way. Ways to prevent and treat this
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR:
Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications
More informationOffice Management of Benign Prostatic Enlargement
Focus on CME at McGill University Office Management of Benign Prostatic Enlargement Symptomatic benign prostate enlargement is a common medical problem encountered in our aging society. Watchful waiting,
More informationOveractive Bladder Syndrome
Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Prolonged release tablets, 4 mg and 8 mg (GITS) Date of FAR:
Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Prolonged release tablets, 4 mg and 8 mg (GITS) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications
More informationP ROLIEVE. Thermodilatation System. The Prolieve System Patient Information is Directed to You, the Patient. A Transurethral Microwave Therapy Device
P ROLIEVE Thermodilatation System A Transurethral Microwave Therapy Device The Prolieve System Patient Information is Directed to You, the Patient. Contents Why am I being treated with the Prolieve Thermodilatation
More informationCase studies: LUTS. Case 1 history. Case 1 - questions. Case 1 - outcome. Case 2 - history. Case 1 learning point 14/07/2015 DR JON REES
Case 1 history Case studies: LUTS DR JON REES A 49 year old male comes to see you he has had gradual deterioration of his flow over the last few years- he saw a colleague of yours 6 weeks ago who recorded
More informationPROSCAR (finasteride) Tablets Initial U.S. Approval: 1992
9631307 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROSCAR safely and effectively. See full prescribing information for PROSCAR. PROSCAR (finasteride)
More informationLower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist
Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms Storage Symptoms Frequency, urgency, incontinence, Nocturia Voiding Symptoms Hesitancy, poor flow, intermittency,
More informationShould flomax be taken at bedtime
Should flomax be taken at bedtime Adults with radiopaque lower ureteral stones of 10 mm or smaller have received tamsulosin 0.4 mg PO at bedtime for 28 days or until definite stone passage (i.e. Prostate
More informationThe Evolution of Combination Therapy. US men eligible for BPH treatment * with projected population changes
The Management of BPH & The Impact of Combination Therapy Results Combination of Avodart and Tamsulosin (CombAT) Medical Therapy of Prostate Symptoms (MTOPS) Dr. Jack Barkin, md, fics, facs, dabu, Mcert
More informationCurrent drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol
Drug review BPH Current drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol Skyline Imaging Ltd The range of drug treatments for BPH, alone
More informationEAU GUIDELINES POCKET EDITION 3
EAU GUIDELINES POCKET EDITION 3 CONTENTS: BENIGN PROSTATIC HYPERPLASIA URINARY INCONTINENCE UROLITHIASIS 2 3 EAU POCKET GUIDELINES POCKET EDITION 3 This is one of a series of convenient pocket size books
More informationThe Enlarged Prostate Symptoms, Diagnosis and Treatment
The Enlarged Prostate Symptoms, Diagnosis and Treatment MAC00031-01 Rev G Financial support for this seminar has been provided by NeoTract, Inc., the manufacturer of the UroLift System. 1 Today s Agenda
More informationKAMIREN PACKAGE LEAFLET: INFORMATION FOR THE USER. What is in this leaflet? 1. WHAT KAMIREN IS AND WHAT IT IS USED FOR
PACKAGE LEAFLET: INFORMATION FOR THE USER KAMIREN 2 mg, 4 mg TABLETS DOXAZOSIN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationEVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT
Basrah Journal Of Surgery EVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT MB, ChB, FIBMS, Assistant Professor
More informationPROSTATIC EMBOLIZATION FOR BENIGN HYPERPLASIA
St. Louis Hospital PROSTATIC EMBOLIZATION FOR BENIGN HYPERPLASIA INITIAL CLINICAL RESULTS Faculty of Medical Sciences New University of Lisbon JOÃO PISCO LUÍS CAMPOS PINHEIRO TIAGO BILHIM HUGO RIO TINTO
More informationRecommended drug treatment of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol
Drug review BPH Recommended drug treatment of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol Skyline Imaging Ltd The development of safe and effective drugs
More informationOveractive bladder can result from one or more of the following causes:
Overactive bladder can affect people of any age; however, it is more common in older people. Effective treatments are available and seeing your doctor for symptoms of overactive bladder often results in
More informationPolicy for Prostatism/Lower Urinary Tract Symptoms in men
NHS Halton Clinical Commissioning Group NHS Liverpool Clinical Commissioning Group NHS St Helens Clinical Commissioning Group NHS South Sefton Clinical Commissioning Group NHS Southport and Formby Clinical
More informationManagement of male LUTS in general practice
17 Management of male LUTS in general practice MARK J. SPEAKMAN AND FAITH MCMEEKIN The initial management of lower urinary tract symptoms in men is usually carried out in primary care. The authors explain
More informationBoard Review with The Chiefs. October 17, 2016 October 23, 2016
Board Review with The Chiefs October 17, 2016 October 23, 2016 Overview Registration Exam Details Test Day Details Study Resources Study Strategies Women s Health Men s Health What to Expect: Exam Registration
More informationLiterature Scan: Drugs for BPH
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationIncreasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP
Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of
More informationManagement of Voiding Problems in Older Men. Dr. John Fenn Consultant, QEH 10 th October, 2005
Management of Voiding Problems in Older Men Dr. John Fenn Consultant, QEH 10 th October, 2005 Voiding Problems Poor stream Hesitancy Straining Incomplete emptying Intermittent micturition Terminal dribbling
More informationTRANSURETHRAL RESECTION OF THE PROSTATE
TRANSURETHRAL RESECTION OF THE PROSTATE A discussion of the operation and the pre and post operative care You and your doctor have considered the possibility that you have a transurethral resection of
More informationPRABHAKAR SINGH*, MANOJ INDURKAR, AMITA SINGH, PALLAVI INDURKAR
Academic Sciences International Journal of Current Pharmaceutical Research ISSN- 0975-7066 Vol 5, Issue 1, 2013 Research Article COMPARISON OF THE EFFICACY AND SAFETY OF TAMSULOSIN (0.4 V/S (and) FINASTERIDE
More informationCauses of Transient Incontinence. Geriatrics: Urinary Incontinence, Dementia, and Delirium. Classification of Established Incontinence
Causes of Transient Geriatrics: Urinary, Dementia, and Delirium Carla Zeilmann, PharmD, BCPS St. Louis College of Pharmacy Therapeutics 3 Fall 2003 D delirium I infection A atrophic urethritis and vaginitis
More informationDIAGNOSED WITH BENIGN PROSTATIC HYPERPLASIA
Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 74 No. 4 pp. 1247ñ1253, 2017 ISSN 0001-6837 Polish Pharmaceutical Society PHARMACOLOGY CLINICAL EVALUATION OF α-1-adrenolytics IN PATIENTS DIAGNOSED WITH
More informationHow healthy is your Prostate? - June 2009
How healthy is your Prostate? - June 2009 Inside this months issue Prostatitis Benign Prostatic Hyperplasia (BPH) Prostate cancer Dietary recommendations Is your Prostate Healthy? The prostate is a small
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationThe PSA, Prostate Cancer Screening, and other Prostate Treatment Secrets!
The PSA, Prostate Cancer Screening, and other Prostate Treatment Secrets Mark Bieri, MD Dilemmas in the screening for prostate cancer, the treatments for Cap, and other prostate problems What is the PSA?
More informationThe PSA, Prostate Cancer Screening, and other Prostate Treatment Secrets! Mark Bieri, MD!
The PSA, Prostate Cancer Screening, and other Prostate Treatment Secrets! Mark Bieri, MD! Dilemmas in the screening for prostate cancer, the treatments for Cap, and other prostate problems! What is the
More informationSee 17 for PATIENT COUNSELING INFORMATION FULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use PRO- CURE safely and effectively. See full prescribing information for PRO- CURE. PRO-CURE (finasteride)
More informationExperience the Innovative Therapy for Benign Prostate Enlargement
Experience the Innovative Therapy for Benign Prostate Enlargement A Guide to Treatment of Benign Prostatic Hyperplasia 1. 2. The Prostate The prostate gland is a part of the male reproductive system. A
More informationAFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options
AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options INTRODUCTION This booklet describes how prostate cancer develops, how it affects the body and the current treatment methods. Although
More information김준철 가톨릭대학교의과대학비뇨기과학교실
비뇨기계자율신경병증의치료 김준철 가톨릭대학교의과대학비뇨기과학교실 Introduction Urologic complications have increasingly become a concern in those affected by DM Genitourinary problems are included among these complications, related
More informationProf dr Aleksandar Raskovic DIRECT VASODILATORS
Prof dr Aleksandar Raskovic DIRECT VASODILATORS Direct vasodilators Minoxidil (one of the most powerful peripheral arterial dilators) Opening of KATP channels, efflux of K, lose of Ca and smooth muscle
More informationTrans Urethral Resection of Prostate (TURP)
Trans Urethral Resection of Prostate (TURP) Patient Information Author ID: SF Leaflet Number: Urol 010 Version: 6 Name of Leaflet: Trans Urethral Resection of Prostate (TURP) Date Produced: March 2018
More informationThe Journal of International Medical Research 2005; 33:
The Journal of International Medical Research 2005; 33: 562 573 A Comparative Study on the Safety and Efficacy of Tamsulosin and Alfuzosin in the Management of Symptomatic Benign Prostatic Hyperplasia:
More informationOverview. Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia. Iain McAuley September 15, 2014
Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia Iain McAuley September 15, 2014 Overview Review of the most recent guidelines for ED and BPH ED Guidelines CUA 2006 AUA 2011
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablation, of prostate, holmium laser, 485 495 African prune tree (Pygeum africanum), 454 455 Alfuzosin, 445 446 Alpha-adrenergic agonists,
More informationMale Lower Urinary Tract Symptoms: Management in primary care and beyond. Daniel Cohen PhD FRCS(Urol) Consultant Urological Surgeon
Male Lower Urinary Tract Symptoms: Management in primary care and beyond Daniel Cohen PhD FRCS(Urol) Consultant Urological Surgeon 1 LUTS Very common: 1/3 men over age of 50 have moderate to severe LUTS
More informationPRODUCT MONOGRAPH PROSCAR. Finasteride tablets, USP. Film-coated Tablets 5 mg. Type II 5α-reductase inhibitor
PRODUCT MONOGRAPH PROSCAR Finasteride tablets, USP Film-coated Tablets 5 mg Type II 5α-reductase inhibitor Merck Canada Inc. 16750 route Transcanadienne Kirkland, QC H9H 4M7 Canada www.merck.ca Date of
More informationSILOFAST Capsules (Silodosin)
Published on: 10 Jul 2014 SILOFAST Capsules (Silodosin) Composition SILOFAST-4 Capsules Each hard gelatin capsule contains: Silodosin 4 mg Approved colours used in capsule shell SILOFAST-8 Capsules Each
More informationGU problems of Mostly Men Notes
GU problems of Mostly Men Notes I. Lower Urinary Tract Infections A. Cystitis 1. Frequency, urgency, hesitancy, back pain, nocturia, suprapubic heaviness or pain 2. E coli (80%), Staph saprophyticus (5-15%),
More informationThe Journal of International Medical Research 2012; 40:
The Journal of International Medical Research 2012; 40: 899 908 Comparison of α-blocker Monotherapy and α-blocker Plus 5α-Reductase Inhibitor Combination Therapy Based on Prostate Volume for Treatment
More information1/3/2008. Karen Burke Priscilla LeMone Elaine Mohn-Brown. Medical-Surgical Nursing Care, 2e Karen Burke, Priscilla LeMone, and Elaine Mohn-Brown
Medical-Surgical Nursing Care Second Edition Karen Burke Priscilla LeMone Elaine Mohn-Brown Chapter 34 Caring for Male Clients with Reproductive System Disorders Benign Prostatic Hyperplasia (BPH) Testosterone
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Alfuzosin HCl Ranbaxy 10 mg tablets, prolonged-release tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg
More informationDr. Aso Urinary Symptoms
Haematuria The presence of blood in the urine (haematuria) is always abnormal and may be the only indication of pathology in the urinary tract. False positive stick tests and the discolored urine caused
More informationPRODUCT MONOGRAPH MINT-FINASTERIDE. finasteride tablets, USP. Film-coated Tablets 5 mg. Type II 5 alpha-reductase inhibitor
PRODUCT MONOGRAPH Pr MINT-FINASTERIDE finasteride tablets, USP Film-coated Tablets 5 mg Type II 5 alpha-reductase inhibitor MINT Pharmaceuticals Inc. Date of Revision: 1093 Meyerside Drive, Unit 1 6 June
More informationRIVA-FINASTERIDE PRODUCT MONOGRAPH. Finasteride. Film-coated Tablets 5 mg. Type II 5α-reductase inhibitor. Date of revision: September 11, 2018
PRODUCT MONOGRAPH Pr RIVA-FINASTERIDE Finasteride Film-coated Tablets 5 mg Type II 5α-reductase inhibitor Laboratoire Riva Inc. 660 Boul. Industriel Blainville, Québec J7C 3V4 www.labriva.com Date of revision:
More informationPharmacology: Genitourinary. Lecturer: JACOBS
Pharmacology: Genitourinary Lecturer: JACOBS 1 Conditions Covered In This Lecture: Benign prostatic hyperplasia (BPH) Erectile dysfunction Urinary Incontinence 2 Prostate Pharmacology: Genitourinary Fibrous,
More informationPROSCAR Merck Sharp & Dhome
PROSCAR Merck Sharp & Dhome 1. NAME OF THE MEDICINAL PRODUCT PROSCAR (finasteride) 2. QUALITATIVE AND QUANTITIVE COMPOSITION Each tablet contains 5 mg of finasteride. 3. PHARMACEUTICAL FORM Blue-coloured,
More informationPROSCAR (FINASTERIDE) TABLETS
9631302 PROSCAR (FINASTERIDE) TABLETS DESCRIPTION PROSCAR * (finasteride), a synthetic 4-azasteroid compound, is a specific inhibitor of steroid Type II 5α-reductase, an intracellular enzyme that converts
More information